Troxerutin-Mediated Complement Pathway Inhibition is a Disease-Modifying Treatment for Inflammatory Arthritis.

AIA score, on the experiment termination day (day 21), showed highly significant improvement ( p < 0.0001) in TXR200 followed by DS ( p = 0.0006) and TXR100 and TXR50 groups (both p = 0.002). 3.2.3 Reduction in Footpad Thickness Upon TXR Treatment Significant reduction of mean footpad thickness in TXR-treated groups was observed in a dose-dependent manner ( Figure 3B ).

also in 132,142 other papers